IMI pushes stakeholders to GETREAL in new €16m 'real clinical data' project
This article was originally published in Scrip
The Innovative Medicines Initiative (IMI) has launched a new €16.3m funded project called GETREAL which will work towards incorporating real-life clinical data into drug development. The goal is to help health technology assessment (HTA) bodies decide how best to grant patients access to new treatments, and through this assist pharmaceutical companies in making better decisions during drug development.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.